← Back to Search

Population Management Platform for Colorectal Cancer Screening

N/A

Recruiting

Led By Adjoa Anyane-Yeboa, MD, MPH

Research Sponsored by Massachusetts General Hospital

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 4 months

Awards & highlights

Study Summary

This trial will use a combination of focus groups and data analysis to examine how well a new population management platform works in primary care clinics.

Who is the study for?

This pilot study is for staff members at partnering community health centers (CHCs) involved in colorectal cancer screening. Eligible participants include administrative leaders, population health managers, data analysts, quality improvement staff, nurses, and providers who are 18 years or older.Check my eligibility

What is being tested?

The study is testing an Implementation Science Strategy to remove obstacles from colorectal cancer screening processes. It involves focus groups with CHC staff and analysis of electronic health records (EHR) and data from a management platform.See study design

What are the potential side effects?

Since this trial focuses on implementing strategies rather than medical treatments, it does not involve typical medication side effects. However, there may be indirect impacts related to workflow changes.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 4 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~4 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

1: Acceptability of Implementation Strategies

2: Feasibility of Implementation Strategies

3: Appropriateness of Implementation Strategies

Secondary outcome measures

: CRC Screening Rates

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Introduction of Implementation StrategiesExperimental Treatment1 Intervention

The investigators will determine the best intervention and strategy (and thus implementers) based on high ranking barriers/facilitators identified in focus groups. A minimum of 2 implementation strategies will be developed and implemented at each level (patient, provider, system) at each site that considers (1) implementation strategy; (2) mechanism in which the strategy impacts the identified determinant (3) the determinant; (4) moderators that may influence the impact of the strategy; (5) the preconditions necessary for successful implementation; and (6) implementation outcomes affected. Each community health center (CHC) will serve as its own separate subject, and individual strategies will be tested using single case experimental design (SCED) at each CHC using component analysis to rapidly test and optimize our strategies. In SCED each subject serves as their own control, an intervention is systematically introduced and withdrawn, and the effects of the intervention are measured.

Group II: Withdrawal of Implementation StrategiesActive Control1 Intervention

In SCED each subject serves as their own control, an intervention is systematically introduced and withdrawn, and the effects of the intervention are measured.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH

13,665 Previous Clinical Trials

40,925,852 Total Patients Enrolled

Massachusetts General HospitalLead Sponsor

2,933 Previous Clinical Trials

13,198,479 Total Patients Enrolled

Adjoa Anyane-Yeboa, MD, MPHPrincipal InvestigatorMass General Hospital // Harvard Medical School

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many medical facilities are administering this clinical investigation?

"This study has 4 active sites. These include Codman Square Health Center in Boston, Brockton Neighborhood Health Centre in Brockton, and Duffy Wellness Center in Hyannis as well as another medical facility."

Answered by AI

Are there any untaken positions in this clinical examination?

"According to clinicaltrials.gov, this trial has been suspended and is no longer accepting volunteers; the original posting was on September 1st 2022 with a final update taking place 31 days later. Despite these circumstances, 1065 other trials are presently recruiting participants for their respective studies."

Answered by AI

Recent research and studies

JNCI: Journal of the National Cancer InstituteJournal

Colorectal Cancer Incidence Patterns in the United States, 1974–2013

Siegel, Rebecca L., Stacey A. Fedewa, William F. Anderson, Kimberly D. Miller, Jiemin Ma, Philip S. Rosenberg, and Ahmedin Jemal. 2017. “Colorectal Cancer Incidence Patterns in the United States, 1974–2013”. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP). doi:10.1093/jnci/djw322.

CA: A Cancer Journal for CliniciansJournal

Colorectal Cancer Statistics, 2020

Siegel, Rebecca L., Kimberly D. Miller, Ann Goding Sauer, Stacey A. Fedewa, Lynn F. Butterly, Joseph C. Anderson, Andrea Cercek, Robert A. Smith, and Ahmedin Jemal. 2020. “Colorectal Cancer Statistics, 2020”. CA: A Cancer Journal for Clinicians. Wiley. doi:10.3322/caac.21601.

Preventive Medicine ReportsJournal

Colorectal Cancer Screening at Community Health Centers: A Survey of Clinicians' Attitudes, Practices, and Perceived Barriers

Brown, Tiffany, Ji Young Lee, Jessica Park, Christine A. Nelson, Mary Ann McBurnie, David T. Liss, Erin O. Kaleba, et al.. 2015. “Colorectal Cancer Screening at Community Health Centers: A Survey of Clinicians' Attitudes, Practices, and Perceived Barriers”. Preventive Medicine Reports. Elsevier BV. doi:10.1016/j.pmedr.2015.09.003.

BMC Family PracticeJournal